Equity Overview
Price & Market Data
Price: $3.39
Daily Change: +$0.01 / 0.29%
Daily Range: $3.26 - $3.51
Market Cap: $188,143,760
Daily Volume: 987,512
Performance Metrics
1 Week: -1.73%
1 Month: 6.92%
3 Months: 4.62%
6 Months: -38.52%
1 Year: -59.04%
YTD: -40.04%
Company Details
Employees: 172
Sector: Health technology
Industry: Biotechnology
Country:
Details
Voyager Therapeutics, Inc., a biotechnology company, focuses on the human genetics for the cure of neurological diseases. The company's lead product candidate is VY7523, an anti-tau antibody program for the treatment of alzheimer's disease (AD). Its product pipeline includes VY1706, a tau silencing gene therapy in preclinical trial for the treatment of alzheimer's disease; SOD1 silencing gene therapy program for treating amyotrophic lateral sclerosis in preclinical trial; and vectorized anti-amyloid antibody early research program for the treatment of AD in preclinical trial. The company is also developing VY-FXN01 for treating friedreich's ataxia; and GBA1 gene replacement program to treat parkinson's disease. In addition, it provides research program for the treatment of Huntington's disease. The company has collaboration and license agreements with Alexion; AstraZeneca Ireland Limited; Novartis Pharma AG; and Neurocrine Biosciences, Inc. for the treatment of various other diseases of the central nervous system. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Lexington, Massachusetts.